Found 24 hits for monomerid = 230120 Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.770 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | >2.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.770 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | >2.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10106559 (2018)
BindingDB Entry DOI: 10.7270/Q2SF2Z7Q |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.770 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | >2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 580 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra... |
US Patent US9850258 (2017)
BindingDB Entry DOI: 10.7270/Q27S7R2C |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.770 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | >2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.260 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US10435415 (2019)
BindingDB Entry DOI: 10.7270/Q2C53P6V |
More data for this Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM230120
(US10106559, Example 73 | US10435415, Example 73 | ...)Show SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(2.22,,;.88,-.77,;-.45,,;-1.78,-.77,;-1.78,-2.31,;-.45,-3.08,;.88,-2.31,;2.22,-3.08,;2.22,-4.62,;.88,-5.39,;3.55,-5.39,;4.89,-4.62,;6.22,-5.39,;6.22,-6.93,;7.55,-4.62,;7.55,-3.08,;8.89,-2.31,;6.22,-2.31,;4.89,-3.08,;3.55,-2.31,;3.55,-.77,;-.45,1.54,;.88,2.31,;2.22,1.54,;.88,3.85,;-.45,4.62,;-.45,6.16,;.88,6.93,;-1.78,6.93,;-1.78,3.85,;-3.25,4.33,;-4.15,3.08,;-5.68,2.92,;-6.31,1.51,;-5.41,.27,;-3.87,.43,;-3.25,1.83,;-1.78,2.31,;-7.8,1.11,;-7.4,-.37,;-8.89,.02,;-8.89,2.2,)| Show InChI InChI=1S/C31H23F3N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(32)11-21(34)26(19)37-30(38)41)24-20(33)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41) | PDB MMDB
NCI pathway Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 0.320 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP... |
US Patent US9334290 (2016)
BindingDB Entry DOI: 10.7270/Q2BK1B6S |
More data for this Ligand-Target Pair | |